


Restoring immune balance in NMOSD patients with a tolerogenic vaccine



PRINCIPLE INVESTIGATORS:
Dr. Maria Hastermann, Dr. Nadine Stempel
Charité, DZNE



SUMMARY

Neuromyelitis optica (NMOSD) is a devastating autoimmune disease that causes blindness and paralysis. Current therapies for NMOSD are not disease-specific, not curative, have side effects that are debilitating or even life-threatening, and come at a high cost (200k/patient/year).

With the goal of preventing disease exacerbation and relapse in NMOSD patients, the team is developing a specific vaccine designed to restore healthy immune homeostasis, with the potential to be curative with minimal side effects.

PROJECT GOALS

- Design optimal vaccine
- Demonstrate efficacy *in vitro*

LONG-TERM GOALS

- Approval by PEI and clinical trial I
- Develop a specific vaccination for Neuromyelitis optica (NMOSD) patients